Company OLIPASS Corporation

Equities

A244460

KR7244460002

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Chiffre d''affaires - Rate of surprise

Sector Bio Therapeutic Drugs

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
519 ^KRW	-2.81%		0.00%	-32.95%

Mar. 18	OLIPASS Corporation announced that it has received KRW 3.5 billion in funding	CI
Mar. 06	OLIPASS Corporation announced that it expects to receive KRW 5 billion in funding	CI

OliPass Corporation is a Korea-based company principally engaged in the research and development of bio medicine. The Company principally manufactures and sells nonopioid analgesic, hyperlipidemia medicine, ocular angiogenesis inhibitor, duchenne dystrophy medicine, cancer immunotherapy medicine and other products. In addition, the Company researches, develops and sells functional cosmetics through the artificial gene platform technology.

Number of employees: 78

KRW in Million	2022	Weight	2023	Weight	Delta
Research 100.0 %	363	15.8 %	5,290	100.0 %	+1,355.69%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	2,296	100.0 %	5,290	100.0 %	+130.38%

Managers	Title	Age	Since
Shin Chung FOU	Founder	64	06-11-15
Young-Yup Park DFI	Director of Finance/CFO	46	-
Heung-Sik Yoon CTO	Chief Tech/Sci/R&D Officer	64	-
Jae-Hwan Choi BRD	Director/Board Member	48	-
Byung-Jun Lee AUD	Comptroller/Controller/Auditor	51	-

Members of the board	Title	Age	Since
Heung-Sik Yoon CTO	Chief Tech/Sci/R&D Officer	64	-
Shin Chung FOU	Founder	64	06-11-15
Se-Bin Oh BRD	Director/Board Member	74	-
In-Seok Park BRD	Director/Board Member	73	-
Young-Go Jung BRD	Director/Board Member	49	-
Jae-Hwan Choi BRD	Director/Board Member	48	-
Young-Yup Park DFI	Director of Finance/CFO	46	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	31,240,601	27,759,936 ( 88.86 %)	2,441 ( 0.007814 %)	88.86 %
Stock B	0	3,070,677	0	3 ( 0.000098 %)

Name	Equities	%	Valuation
Shin Chung 6.854 %	2,141,132	6.854 %	780 785 ₩
Ji-hyun Son 0.9441 %	294,937	0.9441 %	107 552 ₩
Eui-sun Jung 0.7994 %	249,750	0.7994 %	91 074 ₩
Young-rae Kim 0.4380 %	136,831	0.4380 %	49 897 ₩
Su-kyung Jung 0.2961 %	92,500	0.2961 %	33 731 ₩
Sang-wook Son 0.2486 %	77,650	0.2486 %	28 316 ₩
Hyung-wook Min 0.1982 %	61,921	0.1982 %	22 580 ₩
Ji-hee Son 0.1564 %	48,850	0.1564 %	17 814 ₩
Jong-jin Kim 0.1520 %	47,500	0.1520 %	17 321 ₩
Joon-seo Kim 0.1200 %	37,500	0.1200 %	13 675 ₩

Name	Equities	%	Valuation
OLIPASS CORPORATION 0.000124 %	3	0.000124 %	1 ₩

Name	Equities	%	Valuation
OLIPASS CORPORATION 0.00%	3	0.00%	1 $

OliPass Corp.

Ace Dongbaek Tower 16-4 Dongbaekjungang-ro 16beon-gil

17015, Yongin

http://www.olipass.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
OLIPASS CORPORATION	-32.95%	13.24M
VERTEX PHARMACEUTICALS INCORPORATED	+5.33%	111B
REGENERON PHARMACEUTICALS, INC.	+12.11%	106B
BIONTECH SE	-12.56%	22.24B
ARGENX SE	-3.41%	21.25B
GENMAB A/S	-5.71%	18.97B
WUXI APPTEC CO., LTD.	-35.21%	18.52B
BEIGENE, LTD.	-10.86%	16.81B
SAREPTA THERAPEUTICS, INC.	+37.57%	12.54B
LEGEND BIOTECH CORPORATION	-26.24%	8.09B

Bio Therapeutic Drugs